AI-generated from publicly available materials.Emerald, a London-based preventive healthcare platform, has successfully raised €1.66 million, bringing its total funding to €3.44 million. This latest round includes a significant grant from Innovate UK and additional venture capital, highlighting a growing interest in preventive health solutions.
The recent funding comprises an €832.2k grant from Innovate UK, marking the second award the company has received from this organization, alongside an equal amount in venture capital. New investors, including Sequel and Highgoal, participated in this funding round, contributing to an increase in Emerald's valuation. Co-founder and CEO Alexander Badalyan emphasized the demand for accessible healthcare tools that go beyond mere testing, advocating for a holistic approach that empowers individuals to manage their long-term health.
Emerald's platform integrates in-clinic laboratory screenings with a digital interface that consolidates health data, helping users identify potential risks early. Unlike traditional health checks that offer a snapshot in time, Emerald’s model connects ongoing testing with historical data and lifestyle factors, revealing actionable insights. The company has reported substantial growth, processing over 100,000 tests and demonstrating significant health improvements among its users.
With plans to expand its services and reach one million members in the next three years, Emerald is also enhancing its AI capabilities. The Innovate UK grant will specifically aid in developing technology that supports personalized care. This initiative reflects a broader trend in the healthcare sector, where innovative solutions are increasingly recognized as vital for improving health outcomes and accessibility.